Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/REL_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/REL_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/REL_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/REL_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/REL_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/REL_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/REL_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/REL_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000941017 | Prostate | Tumor | response to xenobiotic stimulus | 110/3246 | 462/18723 | 2.13e-04 | 1.84e-03 | 110 |
GO:003806111 | Prostate | Tumor | NIK/NF-kappaB signaling | 42/3246 | 143/18723 | 2.56e-04 | 2.14e-03 | 42 |
GO:005109014 | Prostate | Tumor | regulation of DNA-binding transcription factor activity | 105/3246 | 440/18723 | 2.69e-04 | 2.23e-03 | 105 |
GO:190313113 | Prostate | Tumor | mononuclear cell differentiation | 102/3246 | 426/18723 | 2.87e-04 | 2.32e-03 | 102 |
GO:003461217 | Prostate | Tumor | response to tumor necrosis factor | 66/3246 | 253/18723 | 2.87e-04 | 2.32e-03 | 66 |
GO:005085213 | Prostate | Tumor | T cell receptor signaling pathway | 37/3246 | 123/18723 | 3.47e-04 | 2.74e-03 | 37 |
GO:190152211 | Prostate | Tumor | positive regulation of transcription from RNA polymerase II promoter involved in cellular response to chemical stimulus | 11/3246 | 22/18723 | 4.50e-04 | 3.42e-03 | 11 |
GO:005188115 | Prostate | Tumor | regulation of mitochondrial membrane potential | 25/3246 | 74/18723 | 4.62e-04 | 3.47e-03 | 25 |
GO:190122211 | Prostate | Tumor | regulation of NIK/NF-kappaB signaling | 34/3246 | 112/18723 | 4.92e-04 | 3.64e-03 | 34 |
GO:000181914 | Prostate | Tumor | positive regulation of cytokine production | 109/3246 | 467/18723 | 4.98e-04 | 3.67e-03 | 109 |
GO:005196211 | Prostate | Tumor | positive regulation of nervous system development | 69/3246 | 272/18723 | 4.99e-04 | 3.67e-03 | 69 |
GO:000715915 | Prostate | Tumor | leukocyte cell-cell adhesion | 89/3246 | 371/18723 | 6.33e-04 | 4.52e-03 | 89 |
GO:000608113 | Prostate | Tumor | cellular aldehyde metabolic process | 21/3246 | 60/18723 | 7.59e-04 | 5.20e-03 | 21 |
GO:005159119 | Prostate | Tumor | response to cAMP | 29/3246 | 93/18723 | 7.66e-04 | 5.24e-03 | 29 |
GO:007135617 | Prostate | Tumor | cellular response to tumor necrosis factor | 59/3246 | 229/18723 | 8.15e-04 | 5.51e-03 | 59 |
GO:005085611 | Prostate | Tumor | regulation of T cell receptor signaling pathway | 16/3246 | 41/18723 | 8.25e-04 | 5.56e-03 | 16 |
GO:190303714 | Prostate | Tumor | regulation of leukocyte cell-cell adhesion | 81/3246 | 336/18723 | 9.26e-04 | 6.10e-03 | 81 |
GO:000828614 | Prostate | Tumor | insulin receptor signaling pathway | 34/3246 | 116/18723 | 9.83e-04 | 6.36e-03 | 34 |
GO:002240916 | Prostate | Tumor | positive regulation of cell-cell adhesion | 70/3246 | 284/18723 | 1.06e-03 | 6.87e-03 | 70 |
GO:00429821 | Prostate | Tumor | amyloid precursor protein metabolic process | 29/3246 | 95/18723 | 1.12e-03 | 7.14e-03 | 29 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
REL | SNV | Missense_Mutation | rs758702004 | c.392N>G | p.Asn131Ser | p.N131S | Q04864 | protein_coding | tolerated(0.14) | benign(0.012) | TCGA-A7-A3IZ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
REL | SNV | Missense_Mutation | novel | c.279T>G | p.Phe93Leu | p.F93L | Q04864 | protein_coding | tolerated(0.46) | probably_damaging(0.92) | TCGA-A7-A4SD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxotere | CR |
REL | SNV | Missense_Mutation | | c.1066N>A | p.Glu356Lys | p.E356K | Q04864 | protein_coding | deleterious(0) | possibly_damaging(0.629) | TCGA-AN-A04C-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
REL | insertion | Frame_Shift_Ins | novel | c.728_729insCACCAGATTAATC | p.Phe244ThrfsTer29 | p.F244Tfs*29 | Q04864 | protein_coding | | | TCGA-AR-A0U0-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
REL | insertion | In_Frame_Ins | novel | c.1828_1829insGCCTACAGGGGTTTCAAGTCAAGCAGAATCCTACTATCCCTC | p.Asp610delinsGlyLeuGlnGlyPheGlnValLysGlnAsnProThrIleProHis | p.D610delinsGLQGFQVKQNPTIPH | Q04864 | protein_coding | | | TCGA-B6-A0IA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
REL | SNV | Missense_Mutation | novel | c.65G>A | p.Arg22His | p.R22H | Q04864 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
REL | SNV | Missense_Mutation | | c.469N>G | p.Pro157Ala | p.P157A | Q04864 | protein_coding | tolerated(0.11) | benign(0.127) | TCGA-C5-A1M8-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
REL | SNV | Missense_Mutation | | c.607N>A | p.Glu203Lys | p.E203K | Q04864 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EK-A2PL-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
REL | SNV | Missense_Mutation | | c.946N>A | p.Asp316Asn | p.D316N | Q04864 | protein_coding | tolerated_low_confidence(0.61) | benign(0) | TCGA-JW-A852-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
REL | SNV | Missense_Mutation | | c.1722N>A | p.Met574Ile | p.M574I | Q04864 | protein_coding | tolerated_low_confidence(0.12) | benign(0) | TCGA-LP-A4AV-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |